```
 Winsock to STN



Welcome to STN International!  Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26  MARPAT enhanced with FSORT command
 NEWS  4  NOV 26  CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS  6  DEC 01  ChemPort single article sales feature unavailable
 NEWS  7  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11  FEB 02  Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
 NEWS 12  FEB 02  GENBANK enhanced with SET PLURALS and SET SPELLING
 NEWS 13  FEB 06  Patent sequence location (PSL) data added to USGENE
 NEWS 14  FEB 10  COMPENDEX reloaded and enhanced
 NEWS 15  FEB 11  WTEXTILES reloaded and enhanced
 NEWS 16  FEB 19  New patent-examiner citations in 300,000 CA/CAplus
                  patent records provide insights into related prior
                  art
 NEWS 17  FEB 19  Increase the precision of your patent queries -- use
                  terms from the IPC Thesaurus, Version 2009.01
 NEWS 18  FEB 23  Several formats for image display and print options
                  discontinued in USPATFULL and USPAT2
 NEWS 19  FEB 23  MEDLINE now offers more precise author group fields
                  and 2009 MeSH terms
 NEWS 20  FEB 23  TOXCENTER updates mirror those of MEDLINE - more
                  precise author group fields and 2009 MeSH terms
 NEWS 21  FEB 23  Three million new patent records blast AEROSPACE into
                  STN patent clusters
 NEWS 22  FEB 25  USGENE enhanced with patent family and legal status
                  display data from INPADOCDB
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.
```

```
  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:52:26 ON 03 MAR 2009

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.22       0.22

FILE 'REGISTRY' ENTERED AT 08:52:38 ON 03 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 MAR 2009  HIGHEST RN 1114066-48-6
DICTIONARY FILE UPDATES:   1 MAR 2009  HIGHEST RN 1114066-48-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10588235 str 1.str

L1      STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 08:53:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      209 TO ITERATE

100.0% PROCESSED      209 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L2            2 SEA SSS FUL L1

=> d 12

L2   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   862855-49-0  REGISTRY
ED   Entered STN:  09 Sep 2005
CN   Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-
```

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

FS STEREOSEARCH
MF C30 H30 N4 O5
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	188.41	188.63

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 03 MAR 2009

FILE COVERS 1907 - 3 Mar 2009 VOL 150 ISS 10
FILE LAST UPDATED: 2 Mar 2009 (20090302/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d l3 1-2 ibib ab

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:281174 CAPLUS
DOCUMENT NUMBER: 146:330828
TITLE: Pharmaceutical compositions containing α-4 integrin mediated cell adhesion inhibitors
INVENTOR(S): Ward, Robert William; Witherington, Jason
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980 A	20050805

OTHER SOURCE(S): MARPAT 146:330828
AB The invention relates to a pharmaceutical composition characterized by containing a compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least on of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0=3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against α-4 integrin mediated cell adhesion, and is suitable for use for treatment of α-4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o-tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823674 CAPLUS
DOCUMENT NUMBER: 143:229873
TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases
INVENTOR(S): Ward, Robert William; Witherington, Jason
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------------      ----   --------    --------------------     --------
     WO 2005075438          A1    20050818    WO 2005-JP2194           20050208
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     CA 2554705             A1    20050818    CA 2005-2554705          20050208
     EP 1737826             A1    20070103    EP 2005-710195           20050208
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
     CN 1918133             A     20070221    CN 2005-80004473         20050208
     JP 2007522146          T     20070809    JP 2006-552027           20050208
     US 20080234301         A1    20080925    US 2006-588235           20060803
PRIORITY APPLN. INFO.:                        GB 2004-2812         A   20040209
                                              WO 2005-JP2194       W   20050208
OTHER SOURCE(S):          CASREACT 143:229873; MARPAT 143:229873
AB   Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1,
     R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O,
     S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least
     one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8,
     etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q'
     = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their
     pharmaceutically acceptable salts were prepared  For example, saponification
of Et
     ester II (G = OEt) afforded carboxylic acid II (G = OH).  Compoounds I are
     claimed to be useful as alpha-4 integrin mediated cell adhesion inhibitors
     (no data provided).
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l3 1-2 ibib ab hitstr

L3   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2007:281174  CAPLUS
DOCUMENT NUMBER:          146:330828
TITLE:                    Pharmaceutical compositions containing α-4
                          integrin mediated cell adhesion inhibitors
INVENTOR(S):              Ward, Robert William; Witherington, Jason
PATENT ASSIGNEE(S):       Tanabe Seiyaku Co., Ltd., Japan
SOURCE:                   Jpn. Kokai Tokkyo Koho, 38pp.
                          CODEN: JKXXAF
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.            KIND   DATE        APPLICATION NO.          DATE
     ----------------      ----   --------    --------------------     --------
     JP 2007063268          A     20070315    JP 2006-212923           20060804
PRIORITY APPLN. INFO.:                        JP 2005-227980       A   20050805
OTHER SOURCE(S):          MARPAT 146:330828
AB   The invention relates to a pharmaceutical composition characterized by
containing a
```

compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di-)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di-)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least on of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0=3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against α-4 integrin mediated cell adhesion, and is suitable for use for treatment of α-4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o-tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.

IT 862855-36-5P 862855-49-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. containing α-4 integrin mediated cell adhesion inhibitors)

RN 862855-36-5 CAPLUS
CN Benzenepropanoic acid, β-methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-49-0 CAPLUS
CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:823674 CAPLUS
DOCUMENT NUMBER: 143:229873
TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases
INVENTOR(S): Ward, Robert William; Witherington, Jason
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005075438	A1	20050818	WO 2005-JP2194		20050208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2554705	A1	20050818	CA 2005-2554705		20050208
EP 1737826	A1	20070103	EP 2005-710195		20050208
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1918133	A	20070221	CN 2005-80004473		20050208
JP 2007522146	T	20070809	JP 2006-552027		20050208
US 20080234301	A1	20080925	US 2006-588235		20060803
PRIORITY APPLN. INFO.:			GB 2004-2812	A	20040209
			WO 2005-JP2194	W	20050208

OTHER SOURCE(S): CASREACT 143:229873; MARPAT 143:229873

AB Title compds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et ester II (G = OEt) afforded carboxylic acid II (G = OH). Compoounds I are claimed to be useful as alpha-4 integrin mediated cell adhesion inhibitors (no data provided).

IT 862855-36-5P 862855-49-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-(phenylmethyl)pyrimidinones and related compds. as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases)

RN 862855-36-5 CAPLUS
CN Benzenepropanoic acid, β-methyl-4-[[3-[4-[[[(2-

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-49-0 CAPLUS
CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT